Marrone Bio Innovations (MBII) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 08, 2020
Document And Entity Information
Entity Registrant Name	MARRONE BIO INNOVATIONS INC
Entity Central Index Key	0001441693
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		149,132,683
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 10,120	$ 6,252
Accounts receivable	10,417	5,925
Inventories, net	7,077	8,149
Prepaid expenses and other current assets	1,812	1,390
Total current assets	29,426	21,716
Property, plant and equipment, net	13,184	13,260
Right of use assets, net	4,361	4,567
Intangible assets, net	23,254	23,842
Goodwill	6,740	6,764
Restricted cash	1,560	1,560
Other assets	867	1,008
Total assets	79,392	72,717
Current liabilities:
Accounts payable	6,509	3,379
Accrued liabilities	11,175	12,467
Deferred revenue, current portion	450	427
Lease liability, current portion	933	913
Debt, current portion, net	8,917	3,899
Total current liabilities	27,984	21,085
Deferred revenue, less current portion	1,882	1,986
Lease liability, less current portion	3,742	3,970
Debt, less current portion, net	11,635	11,847
Debt due to related parties	7,300	7,300
Other liabilities	1,984	2,971
Total liabilities	54,527	49,159
Commitments and contingencies
Stockholders' equity:
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at March 31, 2020 and December 31, 2019
Common stock: $0.00001 par value; 250,000 shares authorized, 145,541 and 139,526 shares issued and outstanding as of March 31, 2020 and December 31, 2019	1	1
Additional paid in capital	352,536	344,206
Accumulated deficit	(327,672)	(320,649)
Total stockholders' equity	24,865	23,558
Total liabilities and stockholders' equity	$ 79,392	$ 72,717

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	250,000	250,000
Common stock, shares issued	145,541	139,526
Common stock, shares outstanding	145,541	139,526

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenues	$ 9,650	$ 8,716
Cost of product revenues	4,081	3,729
Gross profit	5,569	4,987
Operating Expenses:
Research, development and patent	3,234	2,942
Selling, general and administrative	7,993	5,674
Total operating expenses	11,227	8,616
Loss from operations	(5,658)	(3,629)
Other (expense) income:
Interest expense	(337)	(306)
Loss on issuance of new warrants	(1,391)
Change in fair value of contingent consideration	237
Other income, net	159	18
Total other (expense) income, net	(1,332)	(288)
Loss before taxes	(6,990)	(3,917)
Income tax expense	(34)
Net loss	$ (7,024)	$ (3,917)
Basic and diluted net loss per common share:	$ (0.05)	$ (0.04)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:	141,572	110,691
Product [Member]
Revenues:
Total revenues	$ 9,535	$ 8,601
License [Member]
Revenues:
Total revenues	$ 115	$ 115

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholder's Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Memeber]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 1	$ 296,409	$ (283,474)	$ 12,936
Balance, shares at Dec. 31, 2018	110,691
Net loss			(3,917)	(3,917)
Share-based compensation		558		558
Balance at Mar. 31, 2019	$ 1	296,967	(287,391)	9,577
Balance, shares at Mar. 31, 2019	110,691
Balance at Dec. 31, 2019	$ 1	344,206	(320,649)	23,558
Balance, shares at Dec. 31, 2019	139,526
Net loss			(7,024)	(7,024)
Share-based compensation		907		907
Net settlement of options		12		12
Net settlement of options, shares	15
Employee stock purchase plan		84		84
Employee stock purchase plan, shares
Financing costs		(64)		(64)
Issuance of common stock in connection with call to exercise warrants		6,000		6,000
Issuance of common stock in connection with call to exercise warrants, shares	6,000
Issuance of new warrants in connection with call to exercise warrants		1,391		1,391
Balance at Mar. 31, 2020	$ 1	$ 352,536	$ (327,673)	$ 24,865
Balance, shares at Mar. 31, 2020	145,541

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Net loss	$ (7,024)	$ (3,917)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	891	455
Gain on disposal of equipment	(9)
Right of use assets amortization	206	199
Share-based compensation	907	558
Non-cash interest expense	61	73
Loss on issuance of August 2019 warrants	1,391
Change in fair value of contingent consideration	(237)
Net changes in operating assets and liabilities:
Accounts receivable	(4,492)	(6,039)
Inventories	1,072	670
Prepaid Expenses and other assets	(281)	(336)
Accounts payable	3,068	726
Accrued and other liabilities	(1,500)	310
Lease Liability	(208)	(150)
Deferred revenue	(137)	(199)
Net cash used in operating activities	(6,292)	(7,650)
Cash flows from investing activities
Payment of future contingent consideration in connection with previous asset purchase	(540)
Sale of property, plant, equipment	2
Purchases of property, plant and equipment	(135)	(116)
Net cash used in investing activities	(673)	(116)
Cash flows from financing activities
Proceeds from secured borrowings	11,319	6,714
Reductions in secured borrowings	(6,322)	(3,511)
Financing costs	(64)
Exercise of stock options	12
Proceeds from employee stock purchase plan	84
Exercise of warrants	6,000
Repayment of debt	(196)	(72)
Net cash provided by financing activities	10,833	3,131
Net (decrease) increase in cash and cash equivalents and restricted cash	3,868	(4,635)
Cash and cash equivalents and restricted cash, beginning of period	7,812	19,781
Cash and cash equivalents and restricted cash, end of period	11,680	15,146
Supplemental disclosure of cash flow information
Cash paid for interest	269	223
Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment included in accounts payable and accrued liabilities	$ 93	$ 10

Summary of Business, Basis of P

Summary of Business, Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Business, Basis of Presentation	1. Summary of Business, Basis of Presentation Marrone Bio Innovations, Inc. (the “Company”), was incorporated under the laws of the State of Delaware on June 15, 2006, and is located in Davis, California. In July 2012, the Company formed a wholly-owned subsidiary, Marrone Michigan Manufacturing LLC (“MMM LLC”), which holds the assets of a manufacturing plant the Company purchased in July 2012. In September 2019 the Company closed its acquisition of Pro Farm Technologies OY, a Finnish limited company, which consisted of Pro Farm Technologies OY and its five subsidiaries Pro Farm International Oy (Finland), Pro Farm OU (Estonia), Pro Farm Technogies Comercio de Insumos Agricolas do Brasil ltda. (Brazil – 99% controlling interest), Pro Farm Inc. (Delaware), and Glinatur SA (Uruguay) (collectively “Pro Farm”). As a result of the acquisition, Pro Farm became a wholly-owned subsidiary of the Company. In December 2019, Pro Farm created its subsidiary Pro Farm Russia, LLC (Russia). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial information as of March 31, 2020, and for the three months ended March 31, 2020 and 2019, has been prepared by the Company, without audit, in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such SEC rules and regulations and accounting principles applicable for interim periods. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The information included in this Quarterly Report on Form 10-Q should be read in connection with the consolidated financial statements and accompanying notes included in the Company’s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2019. In the opinion of management, the condensed consolidated financial statements as of March 31, 2020, and for the three months ended March 31, 2020 and 2019, reflect all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future periods. The Company makes biological crop protection, plant health and plant nutrition products. The Company targets the major markets that use conventional chemical products, including certain agricultural markets where its biological products are used as alternatives for, or mixed with, conventional chemical products. The Company also targets new markets for which (i) there are no available conventional chemical products or (ii) the use of conventional chemical products may not be desirable or permissible either because of health and environmental concerns (including for organically certified crops) or because the development of pest resistance has reduced the efficacy of conventional chemical products. The Company delivers EPA-approved and registered biological crop protection products and other biological products that address the global demand for effective, safe and environmentally responsible products. Going Concern, Liquidity, and Management Plans The accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue to operate under the assumption that there is substantial doubt about its ability to continue as a going concern, for 12 months after the issuance of these condensed consolidated financial statements. This assessment contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from the Company’s substantial doubt about its ability to continue as a going concern. The Company has a limited number of commercialized products and an operating history that includes periods of negative use of operating cash flows, which indicate substantial doubt exists related to the Company’s ability to continue as a going concern for the next 12 months from the date of issuance of these condensed consolidated financial statements. As of March 31, 2020, the Company had an accumulated deficit of $327,672,000, has incurred significant losses since inception, and expects to continue to incur losses for the foreseeable future. The Company funds operations primarily with the proceeds from the sale of its products, promissory notes and term loans, net proceeds from the private placements of convertible notes, as well as with the proceeds from equity instruments. The Company will need to generate significant revenue growth to achieve and maintain profitability. As of March 31, 2020, the Company had a working capital surplus of $1,442,000, including cash and cash equivalents of $10,120,000. In addition, as of March 31, 2020, the Company had debt and debt due to related parties of $20,552,000 and $7,300,000, respectively, for which the underlying debt agreements contain various financial and non-financial covenants, as well as certain material adverse change clauses. As of March 31, 2020, the Company had a total of $1,560,000 of restricted cash relating to these debt agreements (Refer to Note 7). The Company believes that its existing cash and cash equivalents of $6,695,000 at May 8, 2020, together with expected revenues, expected future debt or equity financings and cost management will be sufficient to fund operations as currently planned through one year from the date of the issuance of these condensed consolidated financial statements. The Company anticipates securing additional sources of cash through equity and/or debt financings, collaborative or other funding arrangements with partners, or through other sources of financing, consistent with historic results. However, the Company cannot predict, with certainty, the outcome of its actions to grow revenues, to manage or reduce costs or to secure additional financing from outside sources on terms acceptable to the Company or at all. Further, the Company may continue to require additional sources of cash for general corporate purposes, which may include operating expenses, working capital to improve and promote its commercially available products, advance product candidates, expand international presence and commercialization, general capital expenditures and satisfaction of debt obligations and any potential negative economic impacts from the current COVID-19 pandemic on the Company’s operations. In January 2020, the Company entered into a Second Amendment (the “Amendment”) to the Company’s Invoice Purchase Agreement with LSQ. The most significant changes made to the prior arrangement included an increase in the amount of eligible customer invoices that LSQ may elect to purchase from up to $7,000,000 to up to $20,000,000. In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the “Addendum”) with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company’s unpaid finished goods inventory; (ii) 65% of the appraised value of the Company’s inventory performed on or on behalf of LSQ; or (iii) $3,000,000. (Refer to Note 7) In April 2020, the Company entered into an unsecured note in the amount of $1,723,000 under the Paycheck Protection Program (the “PPP”). The Note may be used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments, mortgage interest payments and interest payments on any other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. While the Company currently believes that its use of the Note proceeds will meet the conditions for forgiveness under the PPP, no assurance is provided that the Company will obtain forgiveness of the Note in whole or in part. (Refer to Note 11). In April 2020, the Company entered into a Warrant Exchange Agreement (the “Warrant Exchange Agreement”) with a group of historical investors. Pursuant to the Warrant Exchange Agreement, the Investors have exchanged certain previously issued and outstanding warrants (the “Prior Warrants”) to purchase an aggregate of up to 45,977,809 shares of the Company’s common stock, for new warrants (the “New Warrants”) to purchase an aggregate of up to 29,881,855 shares of Common Stock (the “Warrant Shares”). All of the New Warrants were issued to the Investors upon execution of the Warrant Exchange Agreement. The New Warrants all have an exercise price of $0.75 per share, and expire in five tranches, as follows: (i) May 1, 2020, with respect to 3,392,581 Warrant Shares, (ii) September 15, 2020, with respect to 2,714,065 Warrant Shares, (iii) December 15, 2020, with respect to 13,027,512 Warrant Shares, (iv) March 15, 2021, with respect to 5,862,380 Warrant Shares, and (v) and December 15, 2021 with respect to 4,885,317 Warrant Shares. In addition, the Investors agreed to exercise all the New Warrants subject to the first tranche, for an aggregate of approximately $2.5 million, on or before their expiration date, which exercise was completed on May 1, 2020. The remaining four tranches of New Warrants reflect an aggregate exercise price of approximately $19.9 million. There can be no assurance that the investors will exercise the new warrants prior to their respective expiration dates. (Refer to Note 8). If the Company breaches any of the covenants contained within any of its debt agreements or if the material adverse change clauses are triggered, the entire unpaid principal and interest balances would be due and payable upon demand. Without entering into a continuation of its current waiver, which expires May 30, 2021, entering into strategic agreements that include significant cash payments upfront, significantly increasing revenues from sales or raising additional capital through the issuance of equity, the Company expects it will exceed its maximum debt-to-worth requirement under the June 2014 Secured Promissory Note with Five Star Bank. Further, a violation of a covenant in one debt agreement will cause the Company to be in violation of certain covenants under each of its other debt agreements. Breach of covenants included in the Company’s debt agreements, which could result in the lenders demanding payment of the unpaid principal and interest balances, will have a material adverse effect upon the Company and would likely require the Company to seek to renegotiate these debt arrangements with the lenders. If such negotiations are unsuccessful, the Company may be required to seek protection from creditors through bankruptcy proceedings. The Company’s inability to maintain compliance with its debt covenants could have a negative impact on the Company’s financial condition and ability to continue as a going concern. The June 2014 Secured Promissory Note contains a material adverse change clause that could be invoked by the lender as a result of the uncertainty related to the Company’s ability to continue as a going concern. If the lender were to declare an event of default, the entire amount of borrowings related to all debt agreements at that time would have to be reclassified as current in the condensed consolidated financial statements. The lender has waived its right to deem recurring losses, liquidity, going concern, and financial condition a material adverse change through May 30, 2021. As a result of the waiver, none of the long-term portion of the Company’s outstanding debt has been reclassified to current in these condensed consolidated financial statements as of March 31, 2020. The Company participates in a heavily regulated and highly competitive crop protection industry and believes that adverse changes in any of the following areas could have a material effect on the Company’s future financial position, results of operations or cash flows: inability to obtain regulatory approvals, increased competition in the biological agricultural product market, market acceptance of the Company’s products, weather and other seasonal factors beyond the Company’s control, litigation or claims against the Company related to intellectual property, patents, products or governmental regulation, and the Company’s ability to support increased growth. The current COVID-19 pandemic, including prolonged domestic and global shelter in place orders, may further increase the risk of adverse changes in the above areas and the Company’s operating results. If the Company becomes unable to continue as a going concern, it may have to liquidate its assets, and stockholders may lose all or part of their investment in the Company’s common stock. Although the Company recognizes that it may need to raise additional funds in the future, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will not be unfavorable. Any future equity financing may result in dilution to existing stockholders and any debt financing may include additional restrictive covenants. Any failure to obtain additional financing or to achieve the revenue growth necessary to fund the Company with cash flows from operations will have a material adverse effect upon the Company and will likely result in a substantial reduction in the scope of the Company’s operations and impact the Company’s ability to achieve its planned business objectives. The actions discussed above cannot be considered to mitigate the substantial doubt raised by its historical operating results and satisfying its estimated liquidity needs for 12 months from the issuance of these condensed consolidated financial statements.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company used significant estimates in accounting for assumptions and estimates associated with acquisition activities in determining the fair values of acquired assets, liabilities and goodwill including its goodwill impairment analysis, assumptions and estimates associated with revenue recognition, including assumptions and estimates used in determining the timing and amount of revenue to recognize for those transactions with variable considerations, fair value of warrants, reserves for inventory obsolescence, fair value of stock-based compensation, and in its going concern, long-lived assets and intangible asset impairment analysis. Concentrations of Credit Risks Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, accounts receivable and debt. The Company deposits its cash and cash equivalents with high credit quality domestic financial institutions with locations in the U.S. and internationally. Such deposits may exceed federal or national deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal. The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 days from the invoice date and are considered past due after this date, although the Company may offer extended terms from time to time. The Company’s principal sources of revenues are its Regalia, Grandevo and Venerate product lines. These three product lines accounted for 89% and 97% of the Company’s total revenues for the three months ended March 31, 2020 and 2019, respectively. Revenues generated from international customers were 14% and 7% for the three months ended March 31, 2020 and 2019, respectively. Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended March 31, 2020 and 2019 consist of the following: CUSTOMER A B C D Three months ended March 31, 2020 23 % 17 % 16 % 13 % 2019 36 % 16 % 12 % 4 % Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either March 31, 2020 or December 31, 2019, which may or may not correspond with any of the customers above, consist of the following: CUSTOMER A B C D March 31, 2020 21 % 17 % 14 % 12 % December 31, 2019 44 % 1 % 5 % 1 % Concentrations of Supplier Dependence The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company currently relies on one supplier for this plant. Such single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s manufacturing plant. While the Company does not have a long-term supply contract with this supplier, the Company does have a long-term business relationship with this supplier. The Company endeavors to keep 6 months of knotweed extract on hand at any given time, but an unexpected disruption in supply including disruptions resulting from the COVID-19 pandemic, could have an effect on Regalia supply and revenues. Although the Company has identified additional sources of raw knotweed, there can be no assurance that the Company will continue to be able to obtain dried extract from China at a competitive price. The Company continues to rely on third parties to formulate Grandevo into spray-dried powders, for all of its production of Venerate, Majestene/Zelto, Stargus and Haven, and from time to time, third-party manufacturers for supplemental production capacity to meet excess seasonal demand and for packaging. The Company’s products have been produced in quantities, and on timelines, sufficient to meet commercial demand and for the Company to satisfy its delivery schedules. However, the Company’s dependence upon others for the production of a portion of its products, or for a portion of the manufacturing process, particularly for drying and for all of its production of Venerate, may adversely affect its ability to satisfy demand and meet delivery obligations, as well as to develop and commercialize new products, on a timely and competitive basis. The Company has not entered into any long-term manufacturing or supply agreements for any of its products, and it may need to enter into additional agreements for the commercial development, manufacturing and sale of its products. There can be no assurance that it can do so on favorable terms, if at all. Pro Farm products are currently partially sourced by suppliers from a manufacturing plant in Russia, in which the Company owns a 12% interest. The Company plans for enough inventory on hand to fill its revenue forecasts for 12 months at any given time, but an unexpected disruption in supply could have an adverse effect on the supply and revenues related to the subsidiary. Although the Company has identified additional manufacturers who are capable suppling the products, there can be no assurance that the Company will continue to be able to obtain products at a competitive price. Acquisitions Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”), governs business combinations when an entity obtains control of a business by acquiring its net asset, or some or all of its equity interest. During the period ended March 31, 2020 we applied ASC 805 in the determination of our acquisition of Pro Farm. ASC 805 requires among other things, defining a business, and upon that determination, recognizing assets acquired and liabilities assumed at fair value as of the acquisition date, determination and recognition of goodwill and that the results of operations of the acquired business be included in the consolidated statements of operations from the respective date of the acquisition. Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows in thousands: MARCH 31, DECEMBER 31, Cash and cash equivalents $ 10,120 $ 6,252 Restricted cash, less current portion 1,560 1,560 Total cash, cash equivalents and restricted cash $ 11,680 $ 7,812 Restricted Cash The Company’s restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its June 2014 Secured Promissory Note. See Note 7 for further discussion. Intangible Assets The Company evaluates intangible assets for impairment at least annually and more often whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. The Company’s intangible assets include customer relationships, patents, trademarks, and in process research and development acquired in 2019 in connection with its asset acquisition of the Jet-Ag and Jet-Oxide product lines and the Company’s acquisition of Pro Farm. The Company has performed an impairment analysis in contemplation of the COVID-19 pandemic and has not recorded an impairment of intangible assets as of March 31, 2020. Impairment of Long-Lived Assets Impairment losses related to long-lived assets are recognized in the event the net carrying value of such assets is not recoverable and exceeds fair value. The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group). If the carrying amount of a long-lived asset (asset group) is considered not recoverable, the impairment loss is measured as the amount by which the carrying value of the asset or asset group exceeds its estimated fair value. The Company has performed an impairment analysis in contemplation of the COVID-19 pandemic and has not recorded impairment of long-lived assets as of March 31, 2020. Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Goodwill is reviewed for impairment on an annual basis as of the first day of the Company’s fiscal fourth quarter or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. The Company has performed an impairment analysis in contemplation of the COVID-19 pandemic and has not recorded impairment in goodwill as of March 31, 2020. Fair Value Accounting Standards Codification (“ASC”) 820, Fair Value Measurements (“ASC 820”), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three-tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability. Deferred Revenue When the Company receives consideration, or such consideration is unconditionally due, from a customer prior to transferring control of goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales after the Company has transferred control of the goods or services to the customer and all revenue recognition criteria are met. The Company’s deferred revenue is broken out as follows (in thousands): MARCH 31, 2020 DECEMBER 31, Product revenues $ 291 $ 299 Financing costs 605 609 License revenues 1,436 1,505 2,332 2,413 Less current portion (450 ) (427 ) $ 1,882 $ 1,986 Research, Development and Patent Expenses Research and development expenses include payroll-related expenses, field trial costs, toxicology costs, regulatory costs, consulting costs and lab costs. Patent expenses include legal costs relating to the patents and patent filing costs. These costs are expensed to operations as incurred. For the three months ended March 31, 2020 and 2019, research and development expenses totaled $2,880,000 and $2,627,000, respectively, and patent expenses totaled $354,000 and $315,000, respectively. Shipping and Handling Costs Amounts billed for shipping and handling are included as a component of product revenues. Related costs for shipping and handling have been included as a component of cost of product revenues. Shipping and handling costs for the three months ended March 31, 2020 and 2019 were $302,000 and $281,000, respectively. Advertising The Company expenses advertising costs as incurred and has included these expenses as a component of selling, general and administrative costs. Advertising costs for the three months ended March 31, 2020 and 2019 were $150,000 and $191,000, respectively. Depreciation and Amortization The Company depreciates and amortizes its capitalized property, plant, and equipment and intangible assets over the useful life of each asset utilizing a straight-line method of expensing. All depreciation and amortization expenses are included in the “Selling, general, and administrative” caption in the statement of operations. As of the three months ended March 31, 2020 and 2019 the total amount of depreciation expense was $304,000 and $455,000, respectively. As of the three months ended March 31, 2020 the total amount of amortization expense was $587,000. No similar expense was incurred for the three months ended March 31, 2019. Segment Information The Company is organized as a single operating segment, whereby its chief operating decision maker assesses the performance of and allocates resources to the business as a whole. Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. The calculation of basic and diluted net loss per share is the same for all periods presented as the effect of certain potential common stock equivalents, which consist of stock options and warrants to purchase common stock and restricted stock units, and contingent shares to be issued in the future are anti-dilutive due to the Company’s net loss position. Anti-dilutive common stock equivalents are excluded from diluted net loss per share. The following table sets forth the potential shares of common stock as of the end of each period presented that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive (in thousands): MARCH 31, 2020 2019 Stock options outstanding 11,529 6,965 Warrants to purchase common stock 52,647 52,647 Restricted stock units outstanding 2,466 1,217 Common shares to be issued in lieu of agent fees 498 498 Employee stock purchase plan 124 — Maximum contingent consideration shares to be issued 5,972 — 73,236 61,327

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Acquisitions	3. Acquisitions The Company contemplates business combinations and acquisition opportunities that align with the Company’s overall strategy. Acquisitions are accounted for under Accounting Standards Codification (“ASC”) 805 Business Combinations based on the facts and circumstances of the transaction. Pro Farm Technologies OY On September 13, 2019, the Company completed its acquisition of 100% of the outstanding shares of Pro Farm Technologies OY, a Finnish limited company (“Pro Farm”) for consideration of approximately $27,543,000 (the “Pro Farm Acquisition”), net of cash acquired. Total consideration consisted of cash payments of $2,843,000 to beneficial owners and $3,178,000 in debt repayments made on behalf of Pro Farm, issuance of a total of 12,666,000 of the Company’s common stock, at the closing market price of $1.59, for an aggregate fair value of $20,299,000, inclusive of 100,000 restricted stock units at a fair value of $159,000 awarded to a key employee and the fair value of up to $7,466,000 of contingent consideration subject to the achievement of certain distributor, revenue, earnings before interest, taxes, depreciation and amortization, and debt and equity milestones from the date of the closing through December 31, 2024, fair valued at $1,395,000. The contingent consideration will be determined at the end of each reporting period and settled through the issuance of the Company’s common shares for each fiscal year in March of the following fiscal year beginning March 2021. Acquisition costs were recorded in “Selling, general and administrative” expenses as incurred. During March 31, 2020 and 2019, respectively, no such costs were incurred in connection with the acquisition. As of March 31, 2020, the estimated fair values of the acquired assets have been finalized. The estimated fair values of the assets acquired, and liabilities assumed are as follows (in thousands): ALLOCATION AT ACQUISITION DATE Accounts receivable $ 583 Inventory 523 Other current assets 211 Investments in subsidiary 537 Intangible assets: Developed technology 16,362 Tradename 2,659 In process research and development 2,713 Goodwill 6,740 Total assets acquired 30,328 Accounts payable 408 Accrued liabilities 779 Debt 1,612 Non-controlling interest (14 ) Net assets acquired $ 27,543 Cash paid, net of cash acquired 5,849 Fair Value of stock consideration 20,299 Fair value of contingent consideration 1,395 Total purchase price $ 27,543 The condensed consolidated statement of operation includes $443,000 of product revenues and $1,136,000 of operating expenses from Pro Farm for the period ending March 31, 2020. The following unaudited pro forma results of operations assume the Pro Farm acquisition had occurred on January 1, 2019 (in thousands): PRO FORMA Product revenues $ 8,937 Cost of product revenues 3,927 Gross profit 5,010 Operating expenses 9,480 Loss from operations $ (4,470 ) Basic and diluted net loss per common share (0.04 ) Significant pro forma adjustments incorporated into the pro forma results above include amortization of acquired intangible assets. These pro forma results are based on estimates and assumptions, which the Company believes are reasonable. They are prepared for comparative purposes only and do not necessarily reflect the results that would have been realized had the Pro Farm Acquisition occurred at the beginning of the period ended March 31, 2019 and are not necessarily indicative of the Company’s consolidated results of operations in future periods.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory	4. Inventory Inventories, net consist of the following (in thousands): MARCH 31, DECEMBER 31, Raw materials $ 1,460 $ 1,610 Work in progress 1,110 783 Finished goods 4,507 5,756 $ 7,077 $ 8,149 As of March 31, 2020 and December 31, 2019, the Company had $320,000 and $248,000, respectively, in reserves against its inventories. For the three months ended March 31, 2020 and 2019, the Company recorded an adjustment of $243,000 and $253,000, respectively, as a result of actual utilization of the Company’s manufacturing plant being less than what is considered normal capacity.

Right-of-use of Assets and Leas

Right-of-use of Assets and Lease Liability	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Right-of-use of Assets and Lease Liability	5. Right-Of-Use of Assets and Lease Liability The components of lease expense were as follows (in thousands): MARCH 31, 2020 2019 Operating lease cost $ 285 $ 297 Short-term lease cost 39 13 Sublease income (10 ) (23 ) $ 314 $ 287 Maturities of lease liabilities for each future calendar year as of March 31, 2020 are as follows (in thousands): OPERATING LEASES 2020, remaining 9 months $ 884 2021 1,202 2022 1,238 2023 1,275 2024 and beyond 867 Total lease payments 5,466 Less: imputed interest 791 Total lease obligation 4,675 Less lease obligation, current portion 933 Lease obligation, non-current portion $ 3,742

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities Accrued liabilities consist of the following (in thousands): MARCH 31, DECEMBER 31, 2020 2019 Accrued compensation $ 3,393 $ 2,730 Accrued warranty costs 369 327 Accrued customer incentives 3,271 5,102 Accrued liabilities, acquisition related 1,966 1,722 Accrued liabilities, other 2,176 2,586 $ 11,175 $ 12,467 The Company warrants the specifications of its products through implied product warranties and has extended product warranties to qualifying customers on a contractual basis. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time product is shipped. The Company’s estimate is based on historical experience and estimates of future warranty costs as a result of increased usage of the Company’s products. During the three months ended March 31, 2020 and 2019, the Company recognized $110,000 and $94,000, respectively in warranty expense associated with product shipments for the period. This expense was reduced by $68,000 and $54,000 for the three months ended March 31, 2020 and 2019, respectively, as a result of the historical usage of warranty reserves being lower than previously estimated and during the three months ended March 31, 2019 the Company settled no warranty claims. No such reduction or settled warranty claims occurred for the three months ended March 31, 2020. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amount, as necessary. Changes in the Company’s accrued warranty costs during the period are as follows (in thousands): Balance at December 31, 2019 $ 327 Warranties issued (released) during the period 42 Settlements made during the period - Balance at March 31, 2020 $ 369 As of March 31, 2020, the contingent consideration in connection with the Company’s acquisition of Pro Farm was recorded at its fair value. The following table provides a reconciliation of the activity for the contingent consideration measured between the most recent reporting period and as of the balance sheet date based on the fair value using significant inputs including the unobservable inputs (Level 3) (in thousands): CONTINGENT CONSIDERATION Fair value at December 31, 2019 $ 1,737 Change in estimated fair value recorded of contingent consideration (237 ) Fair value at March 31, 2020 $ 1,500 The change in fair value for the reporting period was driven by the result of the unobservable fair value model, a Monte Carlo simulation in a risk-neutral framework assuming Geometric Browning Motion. The most significant input to the model was the estimated results of the Pro Farm subsidiary for the periods specified in the share purchase agreement of 2020 – 2023. The following represents other inputs used in determining the fair value of the contingent consideration liability: MARCH 31, DECEMBER 31, 2020 2019 Discount rate 15.1 % 15.2 % Volatility 43.5 % 33.6 % Credit spread 23.0 % 10.8 % Risk-free rate 0.33 % 1.66 % Discount Rate. Estimated Volatility Factor. Credit Spread. Interest Rate. The change in the fair value estimate is recognized in the Company’s consolidated statement of operations in Other Income (expense) under caption Change in fair value of contingent consideration. The contingent consideration will be determined at each reporting period and will be settled with the issuance of the Company’s common shares.

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	7. Debt Debt, including debt due to related parties, consists of the following (in thousands): MARCH 31, DECEMBER 31, 2020 2019 Secured promissory notes (“October 2012 and April 2013 Secured Promissory Notes”) bearing interest at 8.00% per annum, interest and principal due at maturity (December 31, 2022), collateralized by substantially all of the Company’s assets. $ 3,425 $ 3,425 Secured promissory note (“June 2014 Secured Promissory Note”) bearing interest at prime plus 2% (6.25% as of March 31, 2020) per annum, payable monthly through June 2036, collateralized by certain of the Company’s deposit accounts and MMM LLC’s inventories, chattel paper, accounts, 8,338 8,404 Secured revolving borrowing (“LSQ Financing”) bearing interest at (12.80% annually) payable through the lenders direct collection of certain accounts receivable through May 2020, collateralized by substantially all of the Company’s personal property. 8,626 3,629 Senior secured promissory notes due to related parties (“August 2015 Senior Secured Promissory Notes”) bearing interest at 8% per annum, interest and principal payable at maturity (December 31, 2022), collateralized by substantially all of the Company’s assets. 7,300 7,300 Research loan facility (“2018 Research Facility”) bearing interest at 1.00% per annum, interest payments are due annually on the anniversary date of the facility with principal payable in 25% increments on the anniversary date of the facility beginning on the fourth anniversary of the loan (September 2022), net of imputed interest as of March 31, 2020 of $9. 79 81 Financial institution facility (“2018 Bank Facility”) bearing interest at Euribor plus 2.40% (2.60% as of March 31, 2020) per annum, interest payable monthly and principal payable at maturity (May 31, 2020), 60% guaranteed by Export Credit Agency of Finland for a fee of 2.49%. 84 207 Debt, including debt due to related parties 27,852 23,046 Less debt due to related parties, non-current (7,300 ) (7,300 ) Less current portion (8,917 ) (3,899 ) Debt, non-current $ 11,635 $ 11,847 As of March 31, 2020, aggregate contractual future principal payments on the Company’s debt, including debt due to related parties for each calendar year, are due as follows (in thousands): Period ended March 31, 2020 Debt Debt to Related Party 2020 $ 8,939 $ - 2021 325 - 2022 2,796 5,000 2023 391 - 2024 413 - Thereafter 6,902 - Total future principal payments 19,766 5,000 Interest payments included in debt balance (1) 975 2,300 $ 20,741 $ 7,300 (1) Due to the debt extinguishment requirements, the Company has included both accrued interest and future interest in the debt balance for certain outstanding debt. October 2012 and April 2013 Secured Promissory Notes As of March 31, 2020, there have been no changes to the previously reported total principal amount outstanding under the October 2012 and April 2013 Secured Promissory Note, which continues to be $2,450,000. Due to the historical accounting for the promissory note the amount recorded on the condensed consolidated balance sheet of $3,425,000 includes $975,000 in accrued interest, of which as of March 31, 2020 and 2019, a total of $435,000 and $239,000, respectively, had been incurred. The October 2012 and April 2013 Secured Promissory Notes contain representations and warranties by the Company and the lender, certain indemnification provisions in favor of the lenders, customary covenants (including limitations on other debt, liens, acquisitions, investments and dividends), events of default (including payment defaults, breaches of covenants, a material impairment in the lender’s security interest or in the collateral, and events relating to bankruptcy or insolvency), and also restrictive covenants. As of March 31, 2020, the Company is in compliance with all related covenants, or has received an appropriate waiver of these covenants. June 2014 Secured Promissory Note In June 2014, the Company borrowed $10,000,000 pursuant to a business loan agreement and promissory note (“June 2014 Secured Promissory Note”) with Five Star Bank that bears an interest of 6.25% (per annum) as of March 31, 2020. The interest rate is subject to change and is based on the prime rate plus 2.00% per annum. The Company is required to maintain a deposit balance with the Five Star Bank of $1,560,000, which is recorded as restricted cash included in non-current assets. Under this note the Company is required to maintain a current ratio of not less than 1.25-to-1.0, a debt-to-worth ratio of no greater than 4.0-to-1.0 and a loan-to-value ratio of no greater than 70% as determined by Five Star Bank. The Company is also required to comply with certain affirmative and negative covenants under the loan agreement discussed above. In the event of default on the debt, Five Star Bank may declare the entire unpaid principal and interest immediately due and payable. As of March 31, 2019, the Company was in compliance with the “loan to value ratio” covenant, the “current ratio”, the “debt to worth ratio” and, however, the Company has obtained a waiver from the lender for any non-compliance through May 20, 2021. The following table reflects the activity under this note (in thousands): 2020 2019 Principal balance, net at December 31, $ 8,404 $ 8,639 Principal payments (217 ) (225 ) Interest 146 153 Debt discount amortization 5 5 Principal balance, net at March 31, $ 8,338 $ 8,572 LSQ Financing In January 2020, the Company entered into a Second Amendment to the Company’s Invoice Purchase Agreement with LSQ. The amendment, among other things, (i) increased the amount of eligible customer invoices which LSQ may elect to purchase from the Company to up to $20,000,000 of eligible customer invoices from the Company from $7,000,000; (ii) increased the advance rate to 90% from 85% and 70% from 60%, respectively, of the face value of domestic and international receivables being sold; (iii) decreased the invoice purchase fee rate from 0.40% to 0.25%; (iv) increased the funds usage fee from 0.020% to 0.025%; (v) extended the 0% aging and collection fee percentage charged at the time when the purchased invoice is collected from 90 days to 120 days, and increased the fee percentage charged thereafter from 0.35% to 0.75%; and (vi) decreased the early termination fee from 0.75% to 0.50%. In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the “Addendum”) with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company’s unpaid finished goods inventory; (ii) 65% of the appraised value of the Company’s inventory performed on or on behalf of LSQ; or (iii) $3,000,000. Funds advance under the Addendum are subject to a monthly inventory management fee of 0.5% on the average monthly inventory funds available and a daily interest rate of 0.025%. The agreement contains representations and warranties by the Company and LSQ, certain indemnification provisions in favor of LSQ and customary covenants (including limitations on other debt, liens, acquisitions, investments and dividends), and events of default (including payment defaults, breaches of covenants, a material impairment in LSQ’s security interest or in the collateral, and events relating to bankruptcy or insolvency). The Company is in compliance with all terms of the agreement. As of March 31, 2020, $8,626,000 was outstanding under the LSQ Financing.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	8. Warrants On August 6, 2019, the Company entered into a warrant amendment and plan of reorganization agreement (“Warrant Reorganization Agreement”) with certain holders of the February 2018 Warrants. Pursuant to the Warrant Reorganization Agreement, the Company agreed to extend the expiration date under the February 2018 Warrants held by such holders from December 2020 to December 2021, and the holders agreed, at any time the Company’s stock trades above $1.00 and upon request by the Company, to exercise up to 36,600,000 of their respective February 2018 Warrants, in consideration for the delivery of (x) the shares subject to the February 2018 Warrants so exercised and (y) the delivery of new warrants (“August 2019 Warrants”) to purchase such additional number of shares of common stock equal to the amount of shares so exercised and delivered under February 2018 Warrants. Accordingly, up to a maximum of 36,600,000 new shares were issuable pursuant to the August 2019 Warrants. The August 2019 Warrants have a term expiring on January 1, 2023, an exercise price of $1.75 per share, and are first exercisable 180 days after issuance. The August 2019 Warrants are exercisable in cash, provided that they may be exercised via net exercise if the Company does not have a registration statement registering the shares underlying the August 2019 Warrants effective as of June 30, 2020. The Company completed a registration statement registering the shares underlying the August 2019 Warrant among other securities which became effective on March 30, 2020. In August and through December 2019, the Company requested under the Warrant Reorganization Agreement, the exercise of 16,000,000 February 2018 Warrants. In February 2020, the Company requested an additional exercise of 6,000,000 February 2018 Warrants, resulting in the Company issuing an additional 6,000,000 common shares and 6,000,000 August 2019 Warrants (“Exercise 3”). The issuance of the August 2019 Warrants resulted in the Company incurring a non-cash charge of $1,391,000 in connection with the fair value of new warrants. The Company’s fair value of the new warrants issued was estimated utilizing a Black Scholes option pricing model. The following table outlines assumptions utilized for the warrant issuance: THREE MONTHS ENDED MARCH 31, 2020 Expected life (years) 3.01-3.04 Estimated volatility factor 52.9-53.1 % Risk-free interest rate 1.58-1.66 % Expected dividend yield — Expected Life. Estimated Volatility Factor. Risk-Free Interest Rate. Expected Dividend Yield. The following table summarizes information about the Company’s common stock warrants outstanding as of March 31, 2020 (in thousands, except exercise price data): NUMBER OF SHARES SUBJECT TO EXPIRATION WARRANTS EXERCISE DESCRIPTION ISSUE DATE DATE ISSUED PRICE In connection with June 2013 Credit Facility (June 2013 Warrants) June 2013 June 2023 (1) 27 $ 8.40 In connection with August 2015 Senior Secured Promissory Notes (August 2015 Warrants) August 2015 August 2023 4,000 $ 1.91 In connection with October 2012 and April 2013 Secured Promissory Notes (November 2016 Warrants) November 2016 November 2026 125 $ 2.38 In connection with June 2017 Consulting Agreement (November 2017 Warrants) June 2017 June 2027 80 $ 1.10 In connection with February 2018 Financing Transaction (February 2018 Warrants 1) February 2018 December 2020 6,750 $ 1.00 In connection with February 2018 Financing Transaction (February 2018 Warrants 2) February 2018 December 2020 5,065 $ 1.25 In connection with August 2019 Modification of February 2018 Warrants (Warrant Amendment and Plan of Reorganization Agreement) August 2019 December 2021 14,600 $ 1.00 In connection with Exercise 1, 2, & 3 of Call Option under the Warrant Amendment and Plan of Reorganization Agreement (August 2019 Warrants) Various dates starting in August 2019 January 2023 22,000 $ 1.75 52,647 The weighted average remaining contractual life and exercise price for these warrants is 2.09 years and $1.41, respectively. (1) The June 2013 Warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (iii) a sale of all or substantially all of the assets of the Company unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise), hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity. In April 2020, the Company entered into the Warrant Exchange Agreement with certain existing warrant holders, including all parties to the Warrant Reorganization Agreement. Under the warrant exchange agreement, the number of outstanding Company warrants as of March 31, 2020 of 52.6 million was immediately reduced to 36.4 million. Pursuant to the warrant exchange agreement, 46.0 million then outstanding warrants, including all the August 2019 Warrants and all remaining February 2018 Warrants subject to the Warrant Reorganization Agreement were exchanged for 29.9 million new warrants with an exercise price of $0.75 per share. The new warrants have five different expirations dates, three in 2020 and two in 2021.

Share-Based Plans

Share-Based Plans	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Plans	9. Share-Based Plans Under the Company’s Employee Stock Purchase Plan (the “ESPP”), employees may purchase Company stock through payroll deductions over each six-month period beginning on each June 1 and December 1 (the “Offer Period”). The purchase price of the shares will be 85% of the lower of the fair market value of the shares at the beginning or at the end of the Offer Period. As of the three months ended March 31, 2020, the Company recorded stock-based compensation expense of approximately $19,000. As of March 31, 2020, there were options to purchase 11,529,000 shares of common stock outstanding, 2,466,000 restricted stock units outstanding and 7,751,000 share-based awards available for grant under the outstanding equity incentive plans. For the three months ended March 31, 2020 and 2019, the Company recognized share-based compensation of $907,000 and $558,000, respectively. During the three months ended March 31, 2020 and 2019, the Company granted options to purchase 87,000 and 48,000 shares of common stock, respectively, at a weighted average exercise price of $1.04 and $1.59, respectively. During the three months ended March 31, 2020, 15,000 options were exercised at a weighted average exercise price of $0.84. No options were exercised for the three months ended March 31, 2019. The following table summarizes the activity of stock options from December 31, 2019 to March 31, 2020 (in thousands, except weighted average exercise price): WEIGHTED- AVERAGE EXERCISE OPTIONS PRICE Balances at December 31, 2019 11,821 $ 2.53 Options granted 87 1.04 Options exercised (15 ) 0.84 Options cancelled (364 ) 1.58 Balances at March 31, 2020 11,529 $ 2.55 In conjunction with Dr. Pamela Marrone’s announcement of her intention to retire from her position as the Company’s Chief Executive Officer (“CEO”) and an employee of the Company, as of March 31, 2020, the remaining expense to be recognized in future periods in connection with the modification for Ms. Marrone’s stock options is $237,000. The following table summarizes the activity of restricted stock units from December 31, 2019 to March 31, 2020 (in thousands, except weighted average grant date fair value): SHARES OUTSTANDING WEIGHTED AVERAGE GRANT DATE FAIR VALUE Outstanding at December 31, 2019 2,405 $ 1.40 Granted 71 0.82 Exercised - - Forfeited (10 ) 1.08 Outstanding at March 31, 2020 2,466 $ 1.39 The following table summarizes the activity of non-vested restricted stock units from December 31, 2019 to March 31, 2020 (in thousands, except weighted average grant date fair value): WEIGHTED AVERAGE GRANT SHARES DATE FAIR OUTSTANDING VALUE Nonvested at December 31, 2019 711 $ 1.45 Granted 71 0.82 Vested (478 ) 1.43 Forfeited (10 ) 1.08 Nonvested at March 31, 2020 294 $ 1.33

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions August 2015 Senior Secured Promissory Notes As of March 31, 2020, there have been no changes to the previously reported total principal amount outstanding under the August 2015 Senior Secured Promissory Notes, which continues to be $5,000,000. Due to the historical accounting for the promissory note the amount recorded on the condensed consolidated balance sheet of $7,300,000 includes $2,300,000 in accrued interest, of which as of March 31, 2020 and 2019, a total of $1,199,000 and $798,000, respectively, had been incurred. The August 2015 Senior Secured Promissory Notes provide for various events of default, including, among others, default in payment of principal or interest, breach of any representation or warranty by the Company or any subsidiary under any agreement or document delivered in connection with the notes, a continued breach of any other condition or obligation under any loan document, certain bankruptcy, liquidation, reorganization or change of control events, the acquisition by any person or persons acting as group, other than the lenders, of beneficial ownership of 40% or more of the outstanding voting stock of the Company. Upon an event of default, the entire principal and interest may be declared immediately due and payable. As of March 31, 2020, the Company was in compliance with its covenants under the August 2015 Senior Secured Promissory Notes. Warrant Exercise In March 2020, 6,000,000 February 2018 Warrants were exercised upon the Company’s utilization of its call option under the Warrant Reorganization Agreement (See Note 8). As a result of this transaction, the Company issued 6,000,000 common shares and 6,000,000 August 2019 Warrants. Of the warrants exercised, two of the warrant holders, Ospraie and Ardsley, are beneficial owners of 38.9% and 11.5%, respectively, of the Company’s total outstanding common stock as of March 31, 2020. The total number of warrants exercised at the request of the Company by Ospraie and Ardsley represented 5,027,325 and 874,314, shares of common stock, respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events Paycheck Protection Program In April 2020, the Company entered into an unsecured note in the amount of $1,723,000 under the Paycheck Protection Program (the “PPP”). The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (the “SBA”). The loan to the Company was made through Five Star Bank (the “Lender”). The Note may be used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments, mortgage interest payments and interest payments on any other debt obligation that were incurred before February 15, 2020. The Note contains events of default and other conditions customary for a Note of this type. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness may also be subject to further requirements in any regulations and guidelines the SBA may adopt. While the Company currently believes that its use of the Note proceeds will meet the conditions for forgiveness under the PPP, no assurance is provided that the Company will obtain forgiveness of the Note in whole or in part. The Company is in the process of assessing the accounting impact of the transaction. Warrant Exchange Agreement In April 2020, the Company entered into the Warrant Exchange Agreement with the Investors. Pursuant to the Warrant Exchange Agreement, the Investors have exchanged their Prior Warrants to purchase an aggregate of up to 45,977,809 shares of common stock for New Warrants to purchase an aggregate of up to 29,881,855 shares of common stock. All of the New Warrants were issued to the Investors upon execution of the Warrant Exchange Agreement on April 29, 2020. The New Warrants all have an exercise price of $0.75 per share, and expire in five tranches, as follows: (i) May 1, 2020, with respect to 3,392,581 shares, (ii) September 15, 2020, with respect to 2,714,065 shares, (iii) December 15, 2020, with respect to 13,027,512 shares, (iv) March 15, 2021, with respect to 5,862,380 shares, and (v) and December 15, 2021 with respect to 4,885,317 shares. In addition, the Investors have agreed to exercise all the New Warrants subject to the first tranche, for an aggregate of approximately $2.5 million, on or before their expiration date, which was completed on May 1, 2020. The New Warrants are exercisable in cash, provided that they may be exercised via cashless “net” exercise if the Company does not have a registration statement registering the shares underlying the New Warrants effective as of March 31, 2021. In addition, the Company will redeem the New Warrants upon the occurrence of any Fundamental Transaction (as defined in the New Warrants), and the exercise price of the New Warrants will be subject to weighted-average antidilution provisions. The Company is in the process of assessing the accounting impact of the transaction. 2020 Executive Compensation and 2019 Executive Bonus On May 1, 2020, the Company’s Board of Directors (the “Board”), upon the recommendation of Company management, awarded all of its named executive officers (“NEOs”) restricted stock units (“RSUs”) in place of ten percent of their annual base salaries pro-rated for the second, third and fourth quarters of 2020, the remaining 90 percent of which will continue to be paid in cash. Also on May 1, 2020, the Board approved bonus awards for each of the Company’s named executive officers for performance during the fiscal year ended December 31, 2019 based on the recommendation it received from the Compensation Committee (“Compensation Committee”) of the Board. The Board approved of the Compensation Committee’s recommendation, and in its discretion, and in order to further conserve Company resources, determined to pay the bonus awards to the NEOs and certain other officers in the form of RSUs, with the number of RSUs awarded in lieu of cash determined at a rate of $0.71 per share, the closing price of the Company’s common stock on May 1, 2020, the date of grant. The RSUs are fully vested, with settlement and delivery of vested shares upon termination of service with the Company. The Company is in the process of assessing the accounting impact of the transaction. The Company has evaluated its subsequent events from March 31, 2020 through the date these consolidated financial statements were issued, and has determined that there are no subsequent events required to be disclosed in these consolidated financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company used significant estimates in accounting for assumptions and estimates associated with acquisition activities in determining the fair values of acquired assets, liabilities and goodwill including its goodwill impairment analysis, assumptions and estimates associated with revenue recognition, including assumptions and estimates used in determining the timing and amount of revenue to recognize for those transactions with variable considerations, fair value of warrants, reserves for inventory obsolescence, fair value of stock-based compensation, and in its going concern, long-lived assets and intangible asset impairment analysis.
Concentrations of Credit Risks	Concentrations of Credit Risks Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, accounts receivable and debt. The Company deposits its cash and cash equivalents with high credit quality domestic financial institutions with locations in the U.S. and internationally. Such deposits may exceed federal or national deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal. The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 days from the invoice date and are considered past due after this date, although the Company may offer extended terms from time to time. The Company’s principal sources of revenues are its Regalia, Grandevo and Venerate product lines. These three product lines accounted for 89% and 97% of the Company’s total revenues for the three months ended March 31, 2020 and 2019, respectively. Revenues generated from international customers were 14% and 7% for the three months ended March 31, 2020 and 2019, respectively. Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended March 31, 2020 and 2019 consist of the following: CUSTOMER A B C D Three months ended March 31, 2020 23 % 17 % 16 % 13 % 2019 36 % 16 % 12 % 4 % Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either March 31, 2020 or December 31, 2019, which may or may not correspond with any of the customers above, consist of the following: CUSTOMER A B C D March 31, 2020 21 % 17 % 14 % 12 % December 31, 2019 44 % 1 % 5 % 1 %
Concentrations of Supplier Dependence	Concentrations of Supplier Dependence The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company currently relies on one supplier for this plant. Such single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s manufacturing plant. While the Company does not have a long-term supply contract with this supplier, the Company does have a long-term business relationship with this supplier. The Company endeavors to keep 6 months of knotweed extract on hand at any given time, but an unexpected disruption in supply including disruptions resulting from the COVID-19 pandemic, could have an effect on Regalia supply and revenues. Although the Company has identified additional sources of raw knotweed, there can be no assurance that the Company will continue to be able to obtain dried extract from China at a competitive price. The Company continues to rely on third parties to formulate Grandevo into spray-dried powders, for all of its production of Venerate, Majestene/Zelto, Stargus and Haven, and from time to time, third-party manufacturers for supplemental production capacity to meet excess seasonal demand and for packaging. The Company’s products have been produced in quantities, and on timelines, sufficient to meet commercial demand and for the Company to satisfy its delivery schedules. However, the Company’s dependence upon others for the production of a portion of its products, or for a portion of the manufacturing process, particularly for drying and for all of its production of Venerate, may adversely affect its ability to satisfy demand and meet delivery obligations, as well as to develop and commercialize new products, on a timely and competitive basis. The Company has not entered into any long-term manufacturing or supply agreements for any of its products, and it may need to enter into additional agreements for the commercial development, manufacturing and sale of its products. There can be no assurance that it can do so on favorable terms, if at all. Pro Farm products are currently partially sourced by suppliers from a manufacturing plant in Russia, in which the Company owns a 12% interest. The Company plans for enough inventory on hand to fill its revenue forecasts for 12 months at any given time, but an unexpected disruption in supply could have an adverse effect on the supply and revenues related to the subsidiary. Although the Company has identified additional manufacturers who are capable suppling the products, there can be no assurance that the Company will continue to be able to obtain products at a competitive price.
Acquisitions	Acquisitions Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”), governs business combinations when an entity obtains control of a business by acquiring its net asset, or some or all of its equity interest. During the period ended March 31, 2020 we applied ASC 805 in the determination of our acquisition of Pro Farm. ASC 805 requires among other things, defining a business, and upon that determination, recognizing assets acquired and liabilities assumed at fair value as of the acquisition date, determination and recognition of goodwill and that the results of operations of the acquired business be included in the consolidated statements of operations from the respective date of the acquisition.
Cash and Cash Equivalents	Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows in thousands: MARCH 31, DECEMBER 31, Cash and cash equivalents $ 10,120 $ 6,252 Restricted cash, less current portion 1,560 1,560 Total cash, cash equivalents and restricted cash $ 11,680 $ 7,812
Restricted Cash	Restricted Cash The Company’s restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its June 2014 Secured Promissory Note. See Note 7 for further discussion.
Intangible Assets	Intangible Assets The Company evaluates intangible assets for impairment at least annually and more often whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. The Company’s intangible assets include customer relationships, patents, trademarks, and in process research and development acquired in 2019 in connection with its asset acquisition of the Jet-Ag and Jet-Oxide product lines and the Company’s acquisition of Pro Farm. The Company has performed an impairment analysis in contemplation of the COVID-19 pandemic and has not recorded an impairment of intangible assets as of March 31, 2020.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Impairment losses related to long-lived assets are recognized in the event the net carrying value of such assets is not recoverable and exceeds fair value. The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group). If the carrying amount of a long-lived asset (asset group) is considered not recoverable, the impairment loss is measured as the amount by which the carrying value of the asset or asset group exceeds its estimated fair value. The Company has performed an impairment analysis in contemplation of the COVID-19 pandemic and has not recorded impairment of long-lived assets as of March 31, 2020.
Goodwill	Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Goodwill is reviewed for impairment on an annual basis as of the first day of the Company’s fiscal fourth quarter or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. The Company has performed an impairment analysis in contemplation of the COVID-19 pandemic and has not recorded impairment in goodwill as of March 31, 2020.
Fair Value	Fair Value Accounting Standards Codification (“ASC”) 820, Fair Value Measurements (“ASC 820”), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three-tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
Deferred Revenue	Deferred Revenue When the Company receives consideration, or such consideration is unconditionally due, from a customer prior to transferring control of goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales after the Company has transferred control of the goods or services to the customer and all revenue recognition criteria are met. The Company’s deferred revenue is broken out as follows (in thousands): MARCH 31, 2020 DECEMBER 31, Product revenues $ 291 $ 299 Financing costs 605 609 License revenues 1,436 1,505 2,332 2,413 Less current portion (450 ) (427 ) $ 1,882 $ 1,986
Research, Development and Patent Expenses	Research, Development and Patent Expenses Research and development expenses include payroll-related expenses, field trial costs, toxicology costs, regulatory costs, consulting costs and lab costs. Patent expenses include legal costs relating to the patents and patent filing costs. These costs are expensed to operations as incurred. For the three months ended March 31, 2020 and 2019, research and development expenses totaled $2,880,000 and $2,627,000, respectively, and patent expenses totaled $354,000 and $315,000, respectively.
Shipping and Handling Costs	Shipping and Handling Costs Amounts billed for shipping and handling are included as a component of product revenues. Related costs for shipping and handling have been included as a component of cost of product revenues. Shipping and handling costs for the three months ended March 31, 2020 and 2019 were $302,000 and $281,000, respectively.
Advertising	Advertising The Company expenses advertising costs as incurred and has included these expenses as a component of selling, general and administrative costs. Advertising costs for the three months ended March 31, 2020 and 2019 were $150,000 and $191,000, respectively.
Depreciation and Amortization	Depreciation and Amortization The Company depreciates and amortizes its capitalized property, plant, and equipment and intangible assets over the useful life of each asset utilizing a straight-line method of expensing. All depreciation and amortization expenses are included in the “Selling, general, and administrative” caption in the statement of operations. As of the three months ended March 31, 2020 and 2019 the total amount of depreciation expense was $304,000 and $455,000, respectively. As of the three months ended March 31, 2020 the total amount of amortization expense was $587,000. No similar expense was incurred for the three months ended March 31, 2019.
Segment Information	Segment Information The Company is organized as a single operating segment, whereby its chief operating decision maker assesses the performance of and allocates resources to the business as a whole.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. The calculation of basic and diluted net loss per share is the same for all periods presented as the effect of certain potential common stock equivalents, which consist of stock options and warrants to purchase common stock and restricted stock units, and contingent shares to be issued in the future are anti-dilutive due to the Company’s net loss position. Anti-dilutive common stock equivalents are excluded from diluted net loss per share. The following table sets forth the potential shares of common stock as of the end of each period presented that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive (in thousands): MARCH 31, 2020 2019 Stock options outstanding 11,529 6,965 Warrants to purchase common stock 52,647 52,647 Restricted stock units outstanding 2,466 1,217 Common shares to be issued in lieu of agent fees 498 498 Employee stock purchase plan 124 — Maximum contingent consideration shares to be issued 5,972 — 73,236 61,327

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedule of Significant Customer's Revenues and Account Receivable Percentage	Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended March 31, 2020 and 2019 consist of the following: CUSTOMER A B C D Three months ended March 31, 2020 23 % 17 % 16 % 13 % 2019 36 % 16 % 12 % 4 % Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either March 31, 2020 or December 31, 2019, which may or may not correspond with any of the customers above, consist of the following: CUSTOMER A B C D March 31, 2020 21 % 17 % 14 % 12 % December 31, 2019 44 % 1 % 5 % 1 %
Schedule of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows in thousands: MARCH 31, DECEMBER 31, Cash and cash equivalents $ 10,120 $ 6,252 Restricted cash, less current portion 1,560 1,560 Total cash, cash equivalents and restricted cash $ 11,680 $ 7,812
Schedule of Deferred Revenue	The Company’s deferred revenue is broken out as follows (in thousands): MARCH 31, 2020 DECEMBER 31, Product revenues $ 291 $ 299 Financing costs 605 609 License revenues 1,436 1,505 2,332 2,413 Less current portion (450 ) (427 ) $ 1,882 $ 1,986
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table sets forth the potential shares of common stock as of the end of each period presented that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive (in thousands): MARCH 31, 2020 2019 Stock options outstanding 11,529 6,965 Warrants to purchase common stock 52,647 52,647 Restricted stock units outstanding 2,466 1,217 Common shares to be issued in lieu of agent fees 498 498 Employee stock purchase plan 124 — Maximum contingent consideration shares to be issued 5,972 — 73,236 61,327

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	As of March 31, 2020, the estimated fair values of the acquired assets have been finalized. The estimated fair values of the assets acquired, and liabilities assumed are as follows (in thousands): ALLOCATION AT ACQUISITION DATE Accounts receivable $ 583 Inventory 523 Other current assets 211 Investments in subsidiary 537 Intangible assets: Developed technology 16,362 Tradename 2,659 In process research and development 2,713 Goodwill 6,740 Total assets acquired 30,328 Accounts payable 408 Accrued liabilities 779 Debt 1,612 Non-controlling interest (14 ) Net assets acquired $ 27,543 Cash paid, net of cash acquired 5,849 Fair Value of stock consideration 20,299 Fair value of contingent consideration 1,395 Total purchase price $ 27,543
Schedule of Pro Forma Acquisition	The following unaudited pro forma results of operations assume the Pro Farm acquisition had occurred on January 1, 2019 (in thousands): PRO FORMA Product revenues $ 8,937 Cost of product revenues 3,927 Gross profit 5,010 Operating expenses 9,480 Loss from operations $ (4,470 ) Basic and diluted net loss per common share (0.04 )

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories, net consist of the following (in thousands): MARCH 31, DECEMBER 31, Raw materials $ 1,460 $ 1,610 Work in progress 1,110 783 Finished goods 4,507 5,756 $ 7,077 $ 8,149

Right-of-use of Assets and Le_2

Right-of-use of Assets and Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense were as follows (in thousands): MARCH 31, 2020 2019 Operating lease cost $ 285 $ 297 Short-term lease cost 39 13 Sublease income (10 ) (23 ) $ 314 $ 287
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities for each future calendar year as of March 31, 2020 are as follows (in thousands): OPERATING LEASES 2020, remaining 9 months $ 884 2021 1,202 2022 1,238 2023 1,275 2024 and beyond 867 Total lease payments 5,466 Less: imputed interest 791 Total lease obligation 4,675 Less lease obligation, current portion 933 Lease obligation, non-current portion $ 3,742

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): MARCH 31, DECEMBER 31, 2020 2019 Accrued compensation $ 3,393 $ 2,730 Accrued warranty costs 369 327 Accrued customer incentives 3,271 5,102 Accrued liabilities, acquisition related 1,966 1,722 Accrued liabilities, other 2,176 2,586 $ 11,175 $ 12,467
Schedule of Changes in Accrued Warranty Costs	The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amount, as necessary. Changes in the Company’s accrued warranty costs during the period are as follows (in thousands): Balance at December 31, 2019 $ 327 Warranties issued (released) during the period 42 Settlements made during the period - Balance at March 31, 2020 $ 369
Schedule of Derivative Liability Measured at Fair Value Using Unobservable Inputs	The following table provides a reconciliation of the activity for the contingent consideration measured between the most recent reporting period and as of the balance sheet date based on the fair value using significant inputs including the unobservable inputs (Level 3) (in thousands): CONTINGENT CONSIDERATION Fair value at December 31, 2019 $ 1,737 Change in estimated fair value recorded of contingent consideration (237 ) Fair value at March 31, 2020 $ 1,500
Schedule of Fair Value of Derivative Liability	The following represents other inputs used in determining the fair value of the contingent consideration liability: MARCH 31, DECEMBER 31, 2020 2019 Discount rate 15.1 % 15.2 % Volatility 43.5 % 33.6 % Credit spread 23.0 % 10.8 % Risk-free rate 0.33 % 1.66 %

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Debt Including Debt to Related Parties	Debt, including debt due to related parties, consists of the following (in thousands): MARCH 31, DECEMBER 31, 2020 2019 Secured promissory notes (“October 2012 and April 2013 Secured Promissory Notes”) bearing interest at 8.00% per annum, interest and principal due at maturity (December 31, 2022), collateralized by substantially all of the Company’s assets. $ 3,425 $ 3,425 Secured promissory note (“June 2014 Secured Promissory Note”) bearing interest at prime plus 2% (6.25% as of March 31, 2020) per annum, payable monthly through June 2036, collateralized by certain of the Company’s deposit accounts and MMM LLC’s inventories, chattel paper, accounts, 8,338 8,404 Secured revolving borrowing (“LSQ Financing”) bearing interest at (12.80% annually) payable through the lenders direct collection of certain accounts receivable through May 2020, collateralized by substantially all of the Company’s personal property. 8,626 3,629 Senior secured promissory notes due to related parties (“August 2015 Senior Secured Promissory Notes”) bearing interest at 8% per annum, interest and principal payable at maturity (December 31, 2022), collateralized by substantially all of the Company’s assets. 7,300 7,300 Research loan facility (“2018 Research Facility”) bearing interest at 1.00% per annum, interest payments are due annually on the anniversary date of the facility with principal payable in 25% increments on the anniversary date of the facility beginning on the fourth anniversary of the loan (September 2022), net of imputed interest as of March 31, 2020 of $9. 79 81 Financial institution facility (“2018 Bank Facility”) bearing interest at Euribor plus 2.40% (2.60% as of March 31, 2020) per annum, interest payable monthly and principal payable at maturity (May 31, 2020), 60% guaranteed by Export Credit Agency of Finland for a fee of 2.49%. 84 207 Debt, including debt due to related parties 27,852 23,046 Less debt due to related parties, non-current (7,300 ) (7,300 ) Less current portion (8,917 ) (3,899 ) Debt, non-current $ 11,635 $ 11,847
Schedule of Contractual Future Principal Payments	As of March 31, 2020, aggregate contractual future principal payments on the Company’s debt, including debt due to related parties for each calendar year, are due as follows (in thousands): Period ended March 31, 2020 Debt Debt to Related Party 2020 $ 8,939 $ - 2021 325 - 2022 2,796 5,000 2023 391 - 2024 413 - Thereafter 6,902 - Total future principal payments 19,766 5,000 Interest payments included in debt balance (1) 975 2,300 $ 20,741 $ 7,300 (1) Due to the debt extinguishment requirements, the Company has included both accrued interest and future interest in the debt balance for certain outstanding debt.
Schedule of Debt Activity	The following table reflects the activity under this note (in thousands): 2020 2019 Principal balance, net at December 31, $ 8,404 $ 8,639 Principal payments (217 ) (225 ) Interest 146 153 Debt discount amortization 5 5 Principal balance, net at March 31, $ 8,338 $ 8,572

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Fair Value Warrant Assumptions	The following table outlines assumptions utilized for the warrant issuance: THREE MONTHS ENDED MARCH 31, 2020 Expected life (years) 3.01-3.04 Estimated volatility factor 52.9-53.1 % Risk-free interest rate 1.58-1.66 % Expected dividend yield —
Summary of Information About Common Stock Warrants Outstanding	The following table summarizes information about the Company’s common stock warrants outstanding as of March 31, 2020 (in thousands, except exercise price data): NUMBER OF SHARES SUBJECT TO EXPIRATION WARRANTS EXERCISE DESCRIPTION ISSUE DATE DATE ISSUED PRICE In connection with June 2013 Credit Facility (June 2013 Warrants) June 2013 June 2023 (1) 27 $ 8.40 In connection with August 2015 Senior Secured Promissory Notes (August 2015 Warrants) August 2015 August 2023 4,000 $ 1.91 In connection with October 2012 and April 2013 Secured Promissory Notes (November 2016 Warrants) November 2016 November 2026 125 $ 2.38 In connection with June 2017 Consulting Agreement (November 2017 Warrants) June 2017 June 2027 80 $ 1.10 In connection with February 2018 Financing Transaction (February 2018 Warrants 1) February 2018 December 2020 6,750 $ 1.00 In connection with February 2018 Financing Transaction (February 2018 Warrants 2) February 2018 December 2020 5,065 $ 1.25 In connection with August 2019 Modification of February 2018 Warrants (Warrant Amendment and Plan of Reorganization Agreement) August 2019 December 2021 14,600 $ 1.00 In connection with Exercise 1, 2, & 3 of Call Option under the Warrant Amendment and Plan of Reorganization Agreement (August 2019 Warrants) Various dates starting in August 2019 January 2023 22,000 $ 1.75 52,647 The weighted average remaining contractual life and exercise price for these warrants is 2.09 years and $1.41, respectively. (1) The June 2013 Warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (iii) a sale of all or substantially all of the assets of the Company unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise), hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.

Share-Based Plans (Tables)

Share-Based Plans (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock Options Activity	The following table summarizes the activity of stock options from December 31, 2019 to March 31, 2020 (in thousands, except weighted average exercise price): WEIGHTED- AVERAGE EXERCISE OPTIONS PRICE Balances at December 31, 2019 11,821 $ 2.53 Options granted 87 1.04 Options exercised (15 ) 0.84 Options cancelled (364 ) 1.58 Balances at March 31, 2020 11,529 $ 2.55
Summary of Restricted Stock Units Activity	The following table summarizes the activity of restricted stock units from December 31, 2019 to March 31, 2020 (in thousands, except weighted average grant date fair value): SHARES OUTSTANDING WEIGHTED AVERAGE GRANT DATE FAIR VALUE Outstanding at December 31, 2019 2,405 $ 1.40 Granted 71 0.82 Exercised - - Forfeited (10 ) 1.08 Outstanding at March 31, 2020 2,466 $ 1.39
Summary of Non-vested Restricted Stock Units Activity	The following table summarizes the activity of non-vested restricted stock units from December 31, 2019 to March 31, 2020 (in thousands, except weighted average grant date fair value): WEIGHTED AVERAGE GRANT SHARES DATE FAIR OUTSTANDING VALUE Nonvested at December 31, 2019 711 $ 1.45 Granted 71 0.82 Vested (478 ) 1.43 Forfeited (10 ) 1.08 Nonvested at March 31, 2020 294 $ 1.33

Summary of Business, Basis of_2

Summary of Business, Basis of Presentation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

Jan. 31, 2020

Mar. 31, 2020

Dec. 15, 2021

Mar. 15, 2021

Dec. 15, 2020

Sep. 15, 2020

May 08, 2020

May 01, 2020

Apr. 30, 2020

Jan. 30, 2020

Dec. 31, 2019

Sep. 30, 2019

Date of incorporation

Jun. 15, 2006

Accumulated deficit

$ (327,672)

$ (320,649)

Working capital surplus

1,442

Cash and cash equivalents

10,120

6,252

Debt excluding related parties

20,552

Debt due to related parties

7,300

$ 7,300

Restricted cash

$ 1,560

Warrants to purchase of common stock

52,647,000

Warrant exercise price

$ 1.41

Debt maturity date

May 30, 2021

Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Two [Member] | Forecast [Member]

Warrants to purchase of common stock

2,714,065

Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Three [Member] | Forecast [Member]

Warrants to purchase of common stock

13,027,512

Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Four [Member] | Forecast [Member]

Warrants to purchase of common stock

5,862,380

Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Five [Member] | Forecast [Member]

Warrants to purchase of common stock

4,885,317

Warrant Exchange Agreement [Member] | New Warrants [Member] | Remaining Tranche Four [Member]

Warrant aggregate amount

$ 19,900

LSQ Funding Group L.C [Member]

Sale of certain accounts receivable to third-party

$ 20,000

$ 7,000

Agreement descriptions

In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the "Addendum") with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company's unpaid finished goods inventory; (ii) 65% of the appraised value of the Company's inventory performed on or on behalf of LSQ; or (iii) $3,000,000. (Refer to Note 7)

Subsequent Event [Member]

Cash and cash equivalents

$ 6,695

Subsequent Event [Member] | Warrant Exchange Agreement [Member] | Prior Warrants [Member]

Warrants to purchase of common stock

45,977,809

Subsequent Event [Member] | Warrant Exchange Agreement [Member] | New Warrants [Member]

Warrants to purchase of common stock

29,881,855

Subsequent Event [Member] | Warrant Exchange Agreement [Member] | New Warrants [Member] | Five Tranches [Member]

Warrant exercise price

$ 0.75

Subsequent Event [Member] | Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche One [Member]

Warrants to purchase of common stock

3,392,581

Warrant aggregate amount

$ 2,500

Subsequent Event [Member] | Paycheck Protection Program [Member]

Unsecured note

$ 1,723

Pro Farm Technologies OY [Member]

Ownership controlling interest percentage

99.00%

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)Number	Mar. 31, 2019USD ($)
Receivables due period	12 months
Customers accounted for percentage of company's total revenues	12.00%
Concentration risk, supplier	The active ingredient in the Company's Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company currently relies on one supplier for this plant. Such single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company's manufacturing plant.
Research and development expenses	$ 2,880	$ 2,627
Patent expenses	354	315
Shipping and handling costs	302	281
Advertising costs	150	191
Depreciation expense	304	455
Amortization expense	$ 587
Operating segment | Number	1
Sales Revenue Net [Member] | International Customers [Member]
Customers accounted for percentage of company's total revenues	14.00%	7.00%
Sales Revenue Net [Member] | International Customers [Member] | Three Product [Member]
Customers accounted for percentage of company's total revenues	89.00%	97.00%
Maximum [Member]
Receivables due period	120 days

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Significant Customer's Revenues and Account Receivable Percentage (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Customers accounted for percentage of company's total revenues and accounts receivable	12.00%
Customer A [Member] | Sales Revenue Net [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	23.00%	36.00%
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	21.00%		44.00%
Customer B [Member] | Sales Revenue Net [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	17.00%	16.00%
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	17.00%		1.00%
Customer C [Member] | Sales Revenue Net [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	16.00%	12.00%
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	14.00%		5.00%
Customer D [Member] | Sales Revenue Net [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	13.00%	4.00%
Customer D [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Customers accounted for percentage of company's total revenues and accounts receivable	12.00%		1.00%

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 10,120	$ 6,252
Restricted cash, less current portion	1,560	1,560
Total cash, cash equivalents and restricted cash	$ 11,680	$ 7,812	$ 15,146	$ 19,781

Significant Accounting Polici_7

Significant Accounting Policies - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Product revenues	$ 291	$ 299
Financing costs	605	609
License revenues	1,436	1,505
Deferred revenue	2,332	2,413
Less current portion	(450)	(427)
Deferred revenue, less current portion	$ 1,882	$ 1,986

Significant Accounting Polici_8

Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Anti-dilutive securities excluded from computation of earning per share	73,236,000	61,327,000
Stock Options Outstanding [Member]
Anti-dilutive securities excluded from computation of earning per share	11,529,000	6,965,000
Warrants to Purchase Common Stock [Member]
Anti-dilutive securities excluded from computation of earning per share	52,647,000	52,647,000
Restricted Stock Units Outstanding [Member]
Anti-dilutive securities excluded from computation of earning per share	2,466,000	1,217,000
Common Shares to be Issued in Lieu of Agent Fees [Member]
Anti-dilutive securities excluded from computation of earning per share	498,000	498,000
Employee Stock Purchase Plan [Member]
Anti-dilutive securities excluded from computation of earning per share	124,000
Maximum Ccontingent Consideration Shares to be Issued [Member]
Anti-dilutive securities excluded from computation of earning per share	5,972,000

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Sep. 13, 2019	Sep. 13, 2019	Mar. 31, 2020
Acquisition percentage			50.00%
Pro Farm Technologies OY [Member]
Acquisition percentage	100.00%	100.00%
Acquired in cash consideration	$ 27,543
Payment of acquisition cash acquired	2,843
Debt incurred on behalf of acquirer	$ 3,178
Number of shares issued during period	12,666,000
Acquisition market price	$ 1.59	$ 1.59
Issuance of common stock value	$ 20,299
Product revenues			$ 443
Business acquisition on operating expenses			$ 1,136
Pro Farm Technologies OY [Member] | Maximum [Member]
Fair value of contingent consideration	7,466	$ 7,466
Pro Farm Technologies OY [Member] | Key Employee [Member]
Fair value of restricted stock units, shares		100,000
Fair value of restricted stock units, value		$ 159
Pro Farm Technologies OY [Member] | Through December 31,2024 [Member]
Fair value	$ 1,395	$ 1,395

Acquisitions - Schedule of Asse

Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Business Combinations [Abstract]
Accounts receivable	$ 583
Inventory	523
Other current assets	211
Investments in subsidiary	537
Developed technology	16,362
Tradename	2,659
In process research and development	2,713
Goodwill	6,740
Total assets acquired	30,328
Accounts payable	408
Accrued liabilities	779
Debt	1,612
Non-controlling interest	(14)
Net assets acquired	27,543
Cash paid, net of cash acquired	5,849
Fair Value of stock consideration	20,299
Fair value of contingent consideration	1,395
Total purchase price	$ 27,543

Acquisitions - Schedule of Pro

Acquisitions - Schedule of Pro Forma Acquisition (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)$ / shares
Business Combinations [Abstract]
Product revenues	$ 8,937
Cost of product revenues	3,927
Gross profit	5,010
Operating expenses	9,480
Loss from operations	$ (4,470)
Basic and Diluted net loss per common share | $ / shares	$ (0.04)

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Reserves against inventories	$ 320	$ 248
Inventory adjustments recorded	$ 243	$ 253

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,460	$ 1,610
Work in progress	1,110	783
Finished goods	4,507	5,756
Inventories, net	$ 7,077	$ 8,149

Right-of-use of Assets and Le_3

Right-of-use of Assets and Lease Liability - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 285	$ 297
Short-term lease cost	39	13
Sublease income	(10)	(23)
Total operating lease costs	$ 314	$ 287

Right-of-use of Assets and Le_4

Right-of-use of Assets and Lease Liability - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2020, remaining 9 months	$ 884
2021	1,202
2022	1,238
2023	1,275
2024 and beyond	867
Total lease payments	5,466
Less: imputed interest	791
Total lease obligation	4,675
Less lease obligation, current portion	933	$ 913
Lease obligation, non-current portion	$ 3,742	$ 3,970

Accrued Liabilities (Details Na

Accrued Liabilities (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Payables and Accruals [Abstract]
Warranty expense	$ 110	$ 94
Warranty reserve	68	$ 54
Settlement of warrant

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued compensation	$ 3,393	$ 2,730
Accrued warranty costs	369	327
Accrued customer incentives	3,271	5,102
Accrued liabilities, acquisition related	1,966	1,722
Accrued liabilities, other	2,176	2,586
Accrued liabilities, total	$ 11,175	$ 12,467

Accrued Liabilities - Schedul_2

Accrued Liabilities - Schedule of Changes in Accrued Warranty Costs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Payables and Accruals [Abstract]
Balance at December 31, 2019	$ 327
Warranties issued (released) during the period	42
Settlements made during the period
Balance at March 31, 2020	$ 369

Accrued Liabilities - Schedul_3

Accrued Liabilities - Schedule of Derivative Liability Measured at Fair Value Using Unobservable Inputs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Payables and Accruals [Abstract]
Fair value at December 31, 2019	$ 1,737
Change in estimated fair value recorded of contingent consideration	(237)
Fair value at March 31, 2020	$ 1,500

Accrued Liabilities - Schedul_4

Accrued Liabilities - Schedule of Fair Value of Derivative Liability (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Discount rate	15.10%	15.20%
Volatility	43.50%	33.60%
Credit spread	23.00%	10.80%
Risk-free rate	0.33%	1.66%

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 30, 2020	Jun. 30, 2014	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Required deposit balance				$ 1,560	$ 1,560
LSQ Funding Group L.C [Member]
Sale of certain accounts receivable to third-party	$ 20,000	$ 7,000
Notes payable				$ 8,626
Domestic Receivables [Member] | LSQ Funding Group L.C [Member]
Invoice purchase fee percentage	90.00%	85.00%
International Receivables [Member] | LSQ Funding Group L.C [Member]
Invoice purchase fee percentage	70.00%	60.00%
Invoice Purchase Agreement [Member] | LSQ Funding Group L.C [Member]
Debt instrument description	In January 2020, the Company entered into a Second Amendment to the Company's Invoice Purchase Agreement with LSQ. The amendment, among other things, (i) increased the amount of eligible customer invoices which LSQ may elect to purchase from the Company to up to $20,000,000 of eligible customer invoices from the Company from $7,000,000; (ii) increased the advance rate to 90% from 85% and 70% from 60%, respectively, of the face value of domestic and international receivables being sold; (iii) decreased the invoice purchase fee rate from 0.40% to 0.25%; (iv) increased the funds usage fee from 0.020% to 0.025%; (v) extended the 0% aging and collection fee percentage charged at the time when the purchased invoice is collected from 90 days to 120 days, and increased the fee percentage charged thereafter from 0.35% to 0.75%; and (vi) decreased the early termination fee from 0.75% to 0.50%.
Amended Inventory Financing Addendum [Member] | LSQ Funding Group L.C [Member]
Debt instrument description	In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the "Addendum") with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company's unpaid finished goods inventory; (ii) 65% of the appraised value of the Company's inventory performed on or on behalf of LSQ; or (iii) $3,000,000. Funds advance under the Addendum are subject to a monthly inventory management fee of 0.5% on the average monthly inventory funds available and a daily interest rate of 0.025%.
Secured Debt [Member]
Debt instrument description				Under this note the Company's is required to maintain a current ratio of not less than 1.25-to-1.0, a debt-to-worth ratio of no greater than 4.0-to-1.0 and a loan-to-value ratio of no greater than 70% as determined by Five Star Bank.
October 2012 and April 2013 Secured Promissory Notes [Member]
Outstanding principal amount				$ 2,450
Due to promissory note				3,425		$ 3,425
Accrued interest				975		975
Secured promissory notes				$ 435		$ 239
June 2014 Secured Promissory Note [Member] | Secured Debt [Member]
Debt instrument, interest rate				6.25%
June 2014 Secured Promissory Note [Member] | Secured Debt [Member] | Business Loan Agreement [Member]
Debt instrument borrowing amount			$ 10,000,000
Debt instrument, interest rate				6.25%
Required deposit balance				$ 1,560
June 2014 Secured Promissory Note [Member] | Secured Debt [Member] | Business Loan Agreement [Member] | Prime Rate [Member]
Debt instrument, interest rate				2.00%

Debt - Schedule of Debt Includi

Debt - Schedule of Debt Including Debt to Related Parties (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt, including debt due to related parties	$ 20,741
Less debt due to related parties, non-current	(7,300)	$ (7,300)
Debt, non-current	11,635	11,847
Secured Debt [Member]
Debt, including debt due to related parties	27,852	23,046
Less debt due to related parties, non-current	(7,300)	(7,300)
Less current portion	(8,917)	(3,899)
Debt, non-current	11,635	11,847
Secured Debt [Member] | Secured Promissory Notes Interest Rate at 8.00% [Member]
Debt, including debt due to related parties	3,425	3,425
Secured Debt [Member] | June 2014 Secured Promissory Note [Member]
Debt, including debt due to related parties	8,338	8,404
Secured Debt [Member] | Secured Revolving Borrowing Interest Rate at 12.80% Through May 2020 [Member]
Debt, including debt due to related parties	8,626	3,629
Secured Debt [Member] | Senior Secured Promissory Note Interest Rate at 8% [Member]
Debt, including debt due to related parties	7,300	7,300
Secured Debt [Member] | Research Loan Facility Interest Rate at 1.00% [Member]
Debt, including debt due to related parties	79	81
Secured Debt [Member] | 2018 Bank facility [Member]
Debt, including debt due to related parties	$ 84	$ 207

Debt - Schedule of Debt Inclu_2

Debt - Schedule of Debt Including Debt to Related Parties (Details) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Debt instrument, maturity date	May 30, 2021
Secured Debt [Member] | Secured Promissory Notes Interest Rate at 8.00% [Member]
Debt instrument, interest rate	8.00%	8.00%
Debt instrument, maturity date	Dec. 31, 2022	Dec. 31, 2022
Secured Debt [Member] | June 2014 Secured Promissory Note [Member]
Debt instrument, interest rate	6.25%
Debt instrument, maturity date	Jun. 30, 2036	Jun. 30, 2036
Debt instrument, prime rate	2.00%	2.00%
Debt instrument, payment terms	Payable monthly through June 2036	Payable monthly through June 2036
Unamortized debt discount	$ 180	$ 185
Secured Debt [Member] | Secured Revolving Borrowing Interest Rate at 12.80% Through May 2020 [Member]
Debt instrument, interest rate	12.80%	12.80%
Debt instrument, payment terms	Through March 2020
Secured Debt [Member] | Secured Revolving Borrowing Interest Rate at 12.80% Through March 2020 [Member]
Debt instrument, payment terms		Through March 2020
Secured Debt [Member] | Senior Secured Promissory Note Interest Rate at 8% [Member]
Debt instrument, interest rate	8.00%	8.00%
Debt instrument, maturity date	Dec. 31, 2022	Dec. 31, 2022
Secured Debt [Member] | Research Loan Facility Interest Rate at 1.00% [Member]
Debt instrument, interest rate	1.00%	1.00%
Debt instrument, maturity date	Sep. 30, 2022	Sep. 30, 2022
Imputed interest, net	$ 9
Debt instrument interest rate principal payment	25.00%	25.00%
Secured Debt [Member] | 2018 Bank facility [Member]
Debt instrument, interest rate	2.60%
Debt instrument, maturity date	May 31, 2020	May 31, 2020
Debt instrument, prime rate	2.40%	2.40%
Debt instrument interest rate principal payment	2.49%	2.49%
Secured Debt [Member] | Export Credit Agency of Finland for a Fee of 2.49% [Member]
Debt instrument, interest rate	60.00%	60.00%

Debt - Schedule of Contractual

Debt - Schedule of Contractual Future Principal Payments (Details) $ in Thousands	Mar. 31, 2020USD ($)
2020	$ 8,939
2021	325
2022	2,796
2023	391
2024	413
Thereafter	6,902
Total future principal payments	19,766
Interest payments included in debt balance	975	[1]
Debt, including debt due to related parties	20,741
Related Party [Member]
2020
2021
2022	5,000
2023
2024
Thereafter
Total future principal payments	5,000
Interest payments included in debt balance	2,300	[1]
Debt, including debt due to related parties	$ 7,300
[1]	Due to the debt extinguishment requirements, the Company has included both accrued interest and future interest in the debt balance for certain outstanding debt.

Debt - Schedule of Debt Activit

Debt - Schedule of Debt Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Principal balance, net at Ending	$ 20,741
June 2014 Secured Promissory Note [Member]
Principal balance, net at Beginning	8,404	$ 8,639
Principal payments	(217)	(225)
Interest	146	153
Debt discount amortization	5	5
Principal balance, net at Ending	$ 8,338	$ 8,572

Warrants (Details Narrative)

Warrants (Details Narrative) - $ / shares	Aug. 06, 2019	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Apr. 30, 2020	Feb. 29, 2020
Warrants expiration date description			On August 6, 2019, the Company entered into a warrant amendment and plan of reorganization agreement ("Warrant Reorganization Agreement") with certain holders of the February 2018 Warrants. Pursuant to the Warrant Reorganization Agreement, the Company agreed to extend the expiration date under the February 2018 Warrants held by such holders from December 2020 to December 2021
Warrant exercise price		$ 1.41	$ 1.41
Number of warrant shares exercised		52,647,000	52,647,000
Warrant weighted average remaining contractual life			2 years 1 month 2 days
August 2019 Warrants [Member]
Warrants expiration date	Jan. 1, 2023
Warrant exercise price	$ 1.75
Number of warrant shares exercised		6,000,000	6,000,000	6,000,000
Number of shares issued during period		6,000,000		6,000,000
February 2018 Warrants [Member]
Number of warrant shares exercised				16,000,000		6,000,000
Warrant Reorganization Agreement [Member] | February 2018 Warrants [Member]
Stock trades price per share	$ 1
Number of warrant shares exercised		6,000,000	6,000,000
Warrant Reorganization Agreement [Member] | February 2018 Warrants [Member] | Subsequent Event [Member]
Warrant exercise price					$ 0.75
Warrant outstanding					29,900,000
Warrant Reorganization Agreement [Member] | August 2019 Warrants [Member] | Maximum [Member]
Number of warrants exercised	36,600,000
Warrant Exchange Agreement [Member]
Warrant outstanding		52,600,000	52,600,000
Warrant Exchange Agreement [Member] | Subsequent Event [Member]
Warrant outstanding					36,400,000
Warrant Exchange Agreement [Member] | August 2019 Warrants [Member] | Subsequent Event [Member]
Warrant outstanding					46,000,000

Warrants - Schedule of Fair Val

Warrants - Schedule of Fair Value Warrant Assumptions (Details)	Mar. 31, 2020Number
Expected Life (Years) [Member] | Minimum [Member]
Warrants and rights outstanding term	3 years 4 days
Expected Life (Years) [Member] | Maximum [Member]
Warrants and rights outstanding term	3 years 15 days
Estimated Volatility Factor [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input	52.9
Estimated Volatility Factor [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input	53.1
Risk-Free Interest Rate [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input	1.58
Risk-Free Interest Rate [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input	1.66
Expected Dividend Yield [Member]
Warrants and rights outstanding, measurement input

Warrants - Summary of Informati

Warrants - Summary of Information About Common Stock Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Number of shares subject to warrants issued | shares	52,647,000
Exercise price | $ / shares	$ 1.41
June 2013 Warrants [Member]
Class of Warrant or Right [Line Items]
Issue date	2013-06
Expiration date	2023-06	[1]
Number of shares subject to warrants issued | shares	27,000
Exercise price | $ / shares	$ 8.40
August 2015 Warrants [Member]
Class of Warrant or Right [Line Items]
Issue date	2015-08
Expiration date	2023-08
Number of shares subject to warrants issued | shares	4,000,000
Exercise price | $ / shares	$ 1.91
November 2016 Warrants [Member]
Class of Warrant or Right [Line Items]
Issue date	2016-11
Expiration date	2026-11
Number of shares subject to warrants issued | shares	125,000
Exercise price | $ / shares	$ 2.38
November 2017 Warrants [Member]
Class of Warrant or Right [Line Items]
Issue date	2017-06
Expiration date	2027-06
Number of shares subject to warrants issued | shares	80,000
Exercise price | $ / shares	$ 1.10
February 2018 Warrants 1 [Member]
Class of Warrant or Right [Line Items]
Issue date	2018-02
Expiration date	2020-12
Number of shares subject to warrants issued | shares	6,750,000
Exercise price | $ / shares	$ 1
February 2018 Warrants 2 [Member]
Class of Warrant or Right [Line Items]
Issue date	2018-02
Expiration date	2020-12
Number of shares subject to warrants issued | shares	5,065,000
Exercise price | $ / shares	$ 1.25
August 2019 Warrants [Member]
Class of Warrant or Right [Line Items]
Issue date	2019-08
Expiration date	2021-12
Number of shares subject to warrants issued | shares	14,600,000
Exercise price | $ / shares	$ 1
Various Dates Starting in August 2019 [Member]
Class of Warrant or Right [Line Items]
Issue date	2019-08
Expiration date	2023-01
Number of shares subject to warrants issued | shares	22,000,000
Exercise price | $ / shares	$ 1.75
[1]	The June 2013 Warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (iii) a sale of all or substantially all of the assets of the Company unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Companys acquisition or sale or otherwise), hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.

Warrants - Summary of Informa_2

Warrants - Summary of Information About Common Stock Warrants Outstanding (Details) (Parenthetical)	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Subject to acquisition or sales percentage	50.00%

Share-Based Plans (Details Narr

Share-Based Plans (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 907	$ 558
Number of options outstanding	11,529,000		11,821,000
Number of restricted stock units outstanding	2,466,000
Number of shares available for grant	7,751,000
Number of option granted to purchase common stock	87,000	48,000
Number of options weighted-average exercise price granted	$ 1.04	$ 1.59
Number of options exercised	15,000
Weighted Average Exercise Price, Options exercised	$ 0.84
Ms. Marrone's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option value	$ 237
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of purchase price of share on fair market value of share	85.00%
Stock based compensation expense	$ 19

Share-Based Plans - Summary of

Share-Based Plans - Summary of Stock Options Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Number of Options, beginning balance	11,821,000
Number of Options granted	87,000	48,000
Number of Options exercised	(15,000)
Number of Options cancelled	(364,000)
Number of Options, ending balance	11,529,000
Weighted Average Exercise Price, beginning balance	$ 2.53
Weighted Average Exercise Price, granted	1.04	$ 1.59
Weighted Average Exercise Price, exercised	0.84
Weighted Average Exercise Price, cancelled	1.58
Weighted Average Exercise Price, ending balance	$ 2.55

Share-Based Plans - Summary o_2

Share-Based Plans - Summary of Restricted Stock Units Activity (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance | shares	2,405,000
Shares Outstanding, Granted | shares	71,000
Shares Outstanding, Vested | shares
Shares Outstanding, Forfeited | shares	(10,000)
Shares Outstanding, Ending Balance | shares	2,466,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 1.40
Weighted Average Grant Date Fair Value, Granted | $ / shares	0.82
Weighted Average Grant Date Fair Value, Vested | $ / shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	1.08
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 1.39

Share-Based Plans - Summary o_3

Share-Based Plans - Summary of Non-vested Restricted Stock Units Activity (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Shares Outstanding, Granted | shares	71,000
Shares Outstanding, Vested | shares
Weighted Average Grant Date Fair Value, Granted	$ 0.82
Weighted Average Grant Date Fair Value, Vested
Weighted Average Grant Date Fair Value, Forfeited	$ 1.08
Restricted Stock Units Outstanding [Member]
Shares Outstanding, Beginning Balance | shares	711,000
Shares Outstanding, Granted | shares	71,000
Shares Outstanding, Vested | shares	(478,000)
Shares Outstanding, Forfeited | shares	(10,000)
Shares Outstanding, Ending Balance | shares	294,000
Weighted Average Grant Date Fair Value, Beginning Balance	$ 1.45
Weighted Average Grant Date Fair Value, Granted	0.82
Weighted Average Grant Date Fair Value, Vested	1.43
Weighted Average Grant Date Fair Value, Forfeited	1.08
Weighted Average Grant Date Fair Value, Ending Balance	$ 1.33

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	5 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Number of warrant shares exercised	52,647,000
August 2019 Warrants [Member]
Number of warrant shares exercised	6,000,000	6,000,000
Number of shares issued during period	6,000,000	6,000,000
August 2015 Senior Secured Promissory Note [Member]
Outstanding principal amount	$ 5,000
Due to promissory note	7,300		$ 7,300
Accrued interest	2,300		2,300
Secured Promissory Note	$ 1,199		$ 798
Beneficial ownership interest percentage	40.00%
Ospraie [Member]
Beneficial ownership interest percentage	38.90%
Number of warrant shares exercised	5,027,325
Ardsley [Member]
Beneficial ownership interest percentage	11.50%
Number of warrant shares exercised	874,314
Warrant Reorganization Agreement [Member] | February 2018 Warrants [Member]
Number of warrant shares exercised	6,000,000

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 15, 2021	Mar. 15, 2021	Dec. 15, 2020	Sep. 15, 2020	May 01, 2020	Apr. 30, 2020	Mar. 31, 2020
Warrants to purchase of common stock							52,647,000
Warrant exercise price							$ 1.41
Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Two [Member] | Forecast [Member]
Warrants to purchase of common stock				2,714,065
Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Three [Member] | Forecast [Member]
Warrants to purchase of common stock			13,027,512
Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Four [Member] | Forecast [Member]
Warrants to purchase of common stock		5,862,380
Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Five [Member] | Forecast [Member]
Warrants to purchase of common stock	4,885,317
Subsequent Event [Member] | Board of Directors [Member]
Lieu of cash per share					$ 0.71
Subsequent Event [Member] | Warrant Exchange Agreement [Member] | Prior Warrants [Member]
Warrants to purchase of common stock						45,977,809
Subsequent Event [Member] | Warrant Exchange Agreement [Member] | New Warrants [Member]
Warrants to purchase of common stock						29,881,855
Subsequent Event [Member] | Warrant Exchange Agreement [Member] | New Warrants [Member] | Five Tranches [Member]
Warrant exercise price						$ 0.75
Subsequent Event [Member] | Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche One [Member]
Warrants to purchase of common stock					3,392,581
Warrant aggregate amount					$ 2,500
Subsequent Event [Member] | Paycheck Protection Program [Member]
Unsecured note						$ 1,723